Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Ibrutinib in Combination With Ixazomib in Patients With Waldenström Macroglobulinemia

NCT03506373 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03506373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03506373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Ibrutinib in Combination With Ixazomib in Patients With Waldenström Macroglobulinemia
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Terminated
Start date
August 14, 2018
Completion date
February 3, 2026
Enrollment
21 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent waldenstrom macroglobulinemia, refractory waldenstrom macroglobulinemia, waldenstrom macroglobulinemia